Gilead Sciences (GILD): Analyst Comments on Increased Merck (MRK) Competition (ABBV)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Wells Fargo Comments on Read-Through from Merck's Acquisition of Idenix (MRK) (IDIX) (GILD) (ACHN) (XNPT)
June 9, 2014 11:47 AM EDTWells Fargo analyst Brian Abrahams commented on Merck's (NYSE: MRK) acquisition of Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) and read-through for HCV. Gilead Sciences (NASDAQ: GILD), XenoPort, Inc. (NASDAQ: XNPT), and Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) were mentioned in the report.
"Given that MRK already owns a high barriertoresistance, pangenotypic NS5A, we believe this acquisition is primarily for IDIX's nucs and the view that combining them with MRK's... More
Wells Fargo Comments on Read-Through from Merck's Acquisition of Idenix (MRK) (IDIX) (GILD) (ACHN) (XNPT)
June 9, 2014 11:47 AM EDTWells Fargo analyst Brian Abrahams commented on Merck's (NYSE: MRK) acquisition of Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) and read-through for HCV. Gilead Sciences (NASDAQ: GILD), XenoPort, Inc. (NASDAQ: XNPT), and Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) were mentioned in the report.
"Given that MRK already owns a high barriertoresistance, pangenotypic NS5A, we believe this acquisition is primarily for IDIX's nucs and the view that combining them with MRK's... More
Achillion Pharma (ACHN) Gains Following Merck/Idenix Offer
June 9, 2014 7:38 AM EDTAchillion Pharmaceuticals, Inc. (NASDAQ: ACHN) stock gained pre-market after Merck (NYSE: MRK) and Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash. The transaction values Idenix at approximately $3.85 billion.
... MoreMerck (MRK) to Acquire Idenix Pharma (IDIX) for $24.50/Share
June 9, 2014 7:31 AM EDTMerck (NYSE: MRK), known as MSD outside the United States and Canada, and Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), today announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash. The transaction, which values the purchase of Idenix at approximately $3.85 billion, has been approved by the boards of directors of both companies.
Idenix has established a promising portfolio of hepatitis C candidates based on its expertise in nucleoside/nucleotide chemistry and prodrug technologies, said Dr. Roger Perlmutter, president, Merck Research... More
